Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 11/6/15  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Daniel J. Drucker

Wrong Dr. Daniel J. Drucker?

Senior Scientist

Phone: (416) ***-****  
The Lunenfeld-Tanenbaum Research Institute
600 University Avenue
Toronto , Ontario M5G 1X5


Employment History

Board Memberships and Affiliations


  • M.D.
  • M.D. degree
    University of Toronto
163 Total References
Web References
Dr. Daniel ..., 1 Sept 2015 [cached]
Dr. Daniel Drucker
Senior Investigator Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital
Dr. Daniel Drucker
Dr. Drucker is currently a Professor of Medicine at the University of Toronto, who studies a family of hormones produced in the pancreas, gastrointestinal tract and brain at his laboratory in the Lunenfeld Tanenbaum Research Institute at Toronto's Mount Sinai Hospital. He holds a Canada Research Chair in Regulatory Peptides and the Banting and Best Diabetes Centre-Novo Nordisk Chair in Incretin Biology. Research carried out at his laboratory has led to the development of two new classes of therapies for the treatment of Type 2 diabetes and a new therapy for patients with short bowel syndrome. His current work may help patients with Crohn's disease and other intestinal disorders.
Dr. Drucker received his M.D. from the University of Toronto in 1980. He received the Prix Galien Canada Research Award 2008 for his substantial contribution to the diagnosis, prevention or treatment of diseases, the 2009 Clinical Investigator Award from The Endocrine Society and the 2011 Claude Bernard Lecture/Award of the European Association for the Study of Diabetes. In July 2015, Dr. Drucker was named an Officer of the Order of Canada.
Dr. Daniel Drucker, an ..., 3 Mar 2015 [cached]
Dr. Daniel Drucker, an endocrinologist and senior scientist at Mount Sinai Hospital in Toronto, is shown in a handout photo. Researchers are probing a link between bariatric surgery and higher colon cancer risk. THE CANADIAN PRESS/ HO-Mount Sinai Hospital - Dr. Daniel Drucker, an endocrinologist and senior scientist at Mount Sinai Hospital in Toronto, is shown in a handout photo. Researchers are probing a link between bariatric surgery and higher colon cancer risk. THE CANADIAN PRESS/ HO-Mount Sinai Hospital
And that appears to stimulate overproduction of a gut hormone that may spur the growth of polyps in the colon that have a propensity to become malignant, suggests Dr. Daniel Drucker, an endocrinologist at Mount Sinai Hospital in Toronto.
In studies in laboratory mice, a research team led by Drucker found the digestive hormone GLP-1 was "a pretty potent growth factor" for the intestine in the animals, as well as a catalyst for intestinal tumours in other lab mice specially bred to study colorectal cancer.
"If we gave the mice more GLP-1, they got more tumours," said Drucker, a senior scientist at the hospital's Lunenfeld-Tanenbaum Research Institute.
While Drucker is quick to point out that mice aren't humans, he said the animal studies go a long way in providing a biological explanation.
"So if you say under what conditions might a human find themselves with increased levels of GLP-1 and the risk for intestinal tumour formation, probably the best delineated situation is the condition of bariatric surgery," he said, explaining that patients have elevated levels of GLP-1, other digestive hormones and bile acids, which are all known to stimulate intestinal growth.
Calling bariatric surgery the best available treatment for obesity and Type 2 diabetes, Drucker said eligible patients shouldn't shy away from the operation but should ensure they have regular screening for colon cancer afterward.
"We're very conservative. We don't make clinical recommendations based on findings in mice," he stressed. "But we would say that given the already available data that patients with bariatric surgery might have an increased risk of colon cancer and our new findings providing an explanation for why that might happen - have your colonoscopies."
That's also the advice for those taking a class of drugs used for diabetes control that work by activating the GLP-1 receptor to increase insulin and decrease blood glucose.
"It's important to state that GLP-1 doesn't by itself ... cause intestinal tumours," said Drucker. "But what we believe is that if you already have a propensity to form a tumour - so if you had an intestinal polyp, which is very common - then we believe that the growth of that polyp would be increased if the levels of GLP-1 were elevated."
While the research, published Tuesday in the journal Cell Metabolism, needs to be replicated by other researchers and confirmed in humans, he said patients should discuss the potential link between increased GLP-1 and colon cancer with their doctors.
Arisaph Pharmaceuticals : About : Scientific Advisory Board, 7 Dec 2013 [cached]
Daniel Drucker
Daniel J. Drucker, M.D., FRCPC Professor of Medicine, University of Toronto Director, Banting and Best Diabetes Centre, University of Toronto
Dr. Daniel J. Drucker is currently a Professor of Medicine, a member of the Endocrinology Division at the University of Toronto and Director of the Banting and Best Diabetes Centre at the University of Toronto. He is a foremost expert on the subject of enteric hormones. He received training in Internal Medicine and Endocrinology from Johns Hopkins Hospital in Baltimore and Toronto General Hospital, University of Toronto. Following completion of a research fellowship in Molecular Endocrinology at Massachusetts General Hospital, he established his own laboratory research program in 1987 in Toronto. His laboratory studies the synthesis, secretion, and mechanism of action of glucagon-like peptides. Specific areas of interest include how glucagon, GLP-1, GLP-2, and the enzyme DPP IV (dipeptidyl peptidase IV) regulate metabolic pathways that control food intake, nutrient absorption and disposal, and intestinal mucosal integrity. Dr. Drucker is an Editor of the journal Endocrinology, and the recipient of Outstanding Investigator Awards from the Canadian Diabetes Association, the Endocrine Society, and the Canadian Society for Clinical Investigation. He also has been elected to membership in the American Society for Clinical Investigation and the Association of American Physicians. Dr. Drucker received his M.D. degree from the University of Toronto in 1980 and received his FRCPC in Internal Medicine from the Royal College of Physicians and Surgeons of Canada in 1984.
Professor Daniel Drucker, ..., 29 April 2014 [cached]
Professor Daniel Drucker, Banting Medal Award Winner
The American Diabetes Association named University of Toronto Professor Daniel Drucker as recipient of the 2014 Banting Medal for Scientific Achievement Award.
Drucker is only the second Canadian recipient of the award, which is named after the late U of T professor and co-discoverer of insulin, Sir Frederick Banting.
"Daniel Drucker has made huge contributions to diabetes research.
Drucker is known as one of the fathers of incretin therapy, which is used to treat Type-2 diabetes. Incretins are a class of gut-derived hormones that regulate the production of insulin and food ingestion. (Read more on the specifics of Drucker's research)
Long after I'm gone, there will continue to be people at U of T who will be conducting research in incretin biology and diabetes," said Drucker.
Drucker is an Endocrinologist and Professor of Medicine in U of T's Division of Endocrinology, Department of Medicine. He is also a Senior Investigator at the Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital and is the former Director of U of T's Banting and Best Diabetes Centre. He holds the Canada Research Chair in Regulatory Peptides and the inaugural Banting & Best Diabetes Centre-Novo Nordisk Chair in Incretin Biology.
"Certainly we all aim to do important work that has international impact. Receiving this award is external validation and reflects not just my hard work, but really honours the work of my lab and the dedication of our trainees and research associates who have contribute to our success," said Drucker.
"Daniel Drucker's translation work transforms scientific discoveries into new therapies for patients.
"Toronto is a great place to conduct diabetes research," said Drucker.
Drucker will be recognized with this honor at the American Diabetes Association's 74th Scientific Sessions, taking place June 13-17, 2014, at the Moscone Center in San Francisco.
The Year in Review: 2012 Highlights from the Samuel Lunenfeld Research Institute — The Lunenfeld-Tanenbaum Research Institute, 2 Aug 2015 [cached]
Dr. Dan Drucker and Dr. Jim Dennis elected to the Royal Society of Canada
Dr. Drucker has been recognized for his innovative work with glucagon-like peptides and DPP-4 inhibitors in the treatment of diabetes and intestinal disorders. Click here for more information .
Thanks to research by Dr. Daniel Drucker, Senior Lunenfeld Investigator, the FDA has approved a drug to treat patients with short bowel syndrome, a debilitating condition often associated with colon cancer and IBD patients. Click here for more information.
Other People with the name "Drucker":
Other ZoomInfo Searches
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.